Suppr超能文献

人工心脏瓣膜的体外脉动血流测量:实验室间比较

In-Vitro Pulsatile Flow Measurement in Prosthetic Heart Valves: An Inter-Laboratory Comparison.

作者信息

Retta Stephen M, Kepner Jeff, Marquez Salvador, Herman Bruce A, S Shu Mark C, Grossman Laurence W

机构信息

Center for Devices & Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA. Elecctronic correspondence:

Medtronic, Inc., Minneapolis, MN, USA.

出版信息

J Heart Valve Dis. 2017 Jan;26(1):72-80.

Abstract

BACKGROUND AND AIM OF STUDY

One of the first steps in qualifying a new prosthetic valve for eventual clinical use is preclinical flow performance testing in vitro. Such testing is typically performed in an in-vitro test system that simulates the pumping mechanics of the left ventricle of the heart, generally referred to as a pulse duplicator or duplicator. Historically, test results in these systems have varied from duplicator to duplicator. This collaborative effort between heart valve manufacturers and the Food and Drug Administration (FDA) was designed to evaluate the variability of the pulse duplicator test technology for pulsatile flow performance measurement in an interlaboratory round robin.

METHODS

The participants jointly developed and followed a limited test protocol based on accepted methods outlined in the International Standards Organization 5840: Cardiovascular Implants - Cardiac Valve Prostheses, and in the FDA Replacement Heart Valve Guidance. One 25 mm valve, each of four basic designs, was circulated to test centers which included four manufacturers and two FDA duplicators. The pressure drop and regurgitation data were then collected and summarized by the FDA.

RESULTS

Considerable variation was observed in hydrodynamic performance measures of pressure drop across the valve and back flow leakage through the valve among the different duplicators. Despite the variations seen in these measures, the results from all centers showed that the valves conformed to certain minimum performance criteria.

CONCLUSIONS

Despite the fact that the valves would have been judged to have met Minimum Performance Requirements of effective orifice area and regurgitant fraction, as specified in the international standard, variations in measurements existed among duplicators. Valve manufacturers should use a reference valve of similar design in hydrodynamic performance testing to assess the individual measurement conditions in the duplicator.

摘要

研究背景与目的

使新型人工心脏瓣膜最终得以临床应用的首要步骤之一是进行体外临床前血流性能测试。此类测试通常在模拟心脏左心室泵血机制的体外测试系统中进行,该系统一般称为脉动复制器。从历史上看,这些系统的测试结果因脉动复制器的不同而有所差异。心脏瓣膜制造商与美国食品药品监督管理局(FDA)的这项合作旨在通过实验室间循环检验评估脉动复制器测试技术在测量脉动血流性能方面的可变性。

方法

参与者共同制定并遵循了一个基于国际标准化组织5840:心血管植入物 - 心脏瓣膜假体以及FDA心脏瓣膜置换指南中所述公认方法的有限测试方案。将四种基本设计的每种各一个25毫米瓣膜分发给包括四家制造商和两个FDA脉动复制器在内的测试中心。然后由FDA收集并汇总压降和反流数据。

结果

在不同的脉动复制器之间,观察到瓣膜两端的压降和通过瓣膜的反流泄漏等流体动力学性能指标存在相当大的差异。尽管在这些指标上存在差异,但所有中心的结果均表明这些瓣膜符合某些最低性能标准。

结论

尽管按照国际标准,这些瓣膜本应被判定符合有效瓣口面积和反流分数的最低性能要求,但不同脉动复制器之间的测量结果仍存在差异。瓣膜制造商在进行流体动力学性能测试时应使用设计相似的参考瓣膜来评估脉动复制器中的个体测量条件。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验